drugset / Trial / NCT00166725

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

NCT00166725

Phase 2 Completed 40 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

The present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin A. The demonstration of an antisecretory effect of somatostatin analogs could offer a rationale for a large scale randomized study.

Timeline

Start
2004-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide

Indications